ES2533238T3 - Nanopartículas que comprenden ligandos de ARN - Google Patents

Nanopartículas que comprenden ligandos de ARN Download PDF

Info

Publication number
ES2533238T3
ES2533238T3 ES05746540.3T ES05746540T ES2533238T3 ES 2533238 T3 ES2533238 T3 ES 2533238T3 ES 05746540 T ES05746540 T ES 05746540T ES 2533238 T3 ES2533238 T3 ES 2533238T3
Authority
ES
Spain
Prior art keywords
nanoparticles
rna ligands
nucleus
ligands
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05746540.3T
Other languages
English (en)
Inventor
Thomas William Rademacher
Khalid Gumaa
Manuel Martin-Lomas
Soledad Penades
Rafael Ojeda
Africa G. Barrientes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midatech Ltd
Original Assignee
Midatech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midatech Ltd filed Critical Midatech Ltd
Priority claimed from PCT/GB2005/002058 external-priority patent/WO2005116226A2/en
Application granted granted Critical
Publication of ES2533238T3 publication Critical patent/ES2533238T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nanopartículas para su uso en un método de terapia, en donde dichas nanopartículas comprenden un núcleo que incluye átomos metálicos y/o semiconductores, y en donde el núcleo está ligado covalentemente a una pluralidad de ligandos que comprende al menos un ligando de ARN que comprende una molécula de ARNip o de miARN.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
    imagen2
ES05746540.3T 2004-05-24 2005-05-24 Nanopartículas que comprenden ligandos de ARN Expired - Lifetime ES2533238T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57380504P 2004-05-24 2004-05-24
GBGB0411537.4A GB0411537D0 (en) 2004-05-24 2004-05-24 Nanoparticles comprising rna ligands
GB0411537 2004-05-24
US573805P 2004-05-24
PCT/GB2005/002058 WO2005116226A2 (en) 2004-05-24 2005-05-24 Nanoparticles comprising rna ligands

Publications (1)

Publication Number Publication Date
ES2533238T3 true ES2533238T3 (es) 2015-04-08

Family

ID=32607858

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05746540.3T Expired - Lifetime ES2533238T3 (es) 2004-05-24 2005-05-24 Nanopartículas que comprenden ligandos de ARN
ES10181903.5T Expired - Lifetime ES2655069T3 (es) 2004-05-24 2005-05-24 Nanopartículas que comprenden ligandos de ARN

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10181903.5T Expired - Lifetime ES2655069T3 (es) 2004-05-24 2005-05-24 Nanopartículas que comprenden ligandos de ARN

Country Status (3)

Country Link
CN (2) CN102872463B (es)
ES (2) ES2533238T3 (es)
GB (1) GB0411537D0 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
EP2365803B1 (en) 2008-11-24 2017-11-01 Northwestern University Polyvalent rna-nanoparticle compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN102449170A (zh) * 2009-04-15 2012-05-09 西北大学 寡核苷酸功能化的纳米颗粒的递送
CN102631687A (zh) * 2012-05-07 2012-08-15 西安电子科技大学 一种靶向转运microRNA的多功能磁性纳米载体及制备方法和应用
US20150126589A1 (en) * 2012-06-08 2015-05-07 Ethris Gmbh Pulmonary Delivery of Messenger RNA
EP2865759B1 (en) * 2012-06-20 2017-05-17 NapaJen Pharma, Inc. Nucleic acid complex and nucleic acid-polysaccharide complex
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN111110846B (zh) 2018-10-30 2021-07-23 国家纳米科学中心 一种金属-核酸纳米颗粒及其制备方法和用途
CN113413467A (zh) * 2021-07-01 2021-09-21 清华大学 一种无载体mRNA递送方法
CN116077519A (zh) * 2022-12-13 2023-05-09 西安交通大学医学院第一附属医院 一种纳米金佐剂联合siRNA-PEX5的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737598T2 (de) * 1996-07-29 2007-12-27 Nanosphere Inc., Skokie Nanopartikel mit daran angehefteten oligonukleotiden sowie deren verwendungen
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles

Also Published As

Publication number Publication date
CN102872463B (zh) 2015-04-08
CN101180400A (zh) 2008-05-14
CN102872463A (zh) 2013-01-16
ES2655069T3 (es) 2018-02-16
CN101180400B (zh) 2013-07-10
GB0411537D0 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
ES2533238T3 (es) Nanopartículas que comprenden ligandos de ARN
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2629749T3 (es) Inmunidad tumoral
ES2500441T3 (es) Preparación líquida que comprende un complejo de pimobendano y ciclodextrina
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
CL2009000040A1 (es) Uso del compuesto 2,2-dimetil-n-((s)-6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-il)-n'-(2,2,3,3,3-pentafluor-propil)-malonamida para el tratamiento del cancer, en particular de tumores solidos, metodos de fabricacion y kit que lo contiene.
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
ES2533097T5 (es) Sistema de codificación magnética con depósito de áreas magnéticas producidas mediante por lo menos dos tipos de tinta magnética con diferentes campos coercitivos, depositadas en un recubrimiento por lo menos parcial
ES2495743T3 (es) Fosfaplatinos y su uso en el tratamiento de cánceres resistentes a cisplatino y carboplatino
BRPI0918555A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ECSP088598A (es) Derivados de piridazinona
CR8559A (es) Pirazolopirimidinas
ES2531516T3 (es) Uso de escina
JP2007510667A5 (es)
AR052367A1 (es) Metodo para conformar articulo abrasivo con estructura
ES2629309T3 (es) Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora
ES2564521T3 (es) Métodos y composiciones para mejorar la entrada de aire en mezclas de cemento
ES2494915T3 (es) P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina